Inactive Instrument

News NurExone Biologic Inc. Toronto S.E.

Equities

ENER

CA29278Q1063

Summary

Unlock all the news: Be the first to know and act before the market!

NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders	Jun. 04	AQ
NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials	May. 29	AQ
NurExone Biologic Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 29	CI
NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations	May. 17	AQ
NurExone Biologic Announces OTCQB Listing And DTC Eligibility	Apr. 25	MT
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility	Apr. 25	AQ
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine	Apr. 22	AQ
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine	Apr. 19	AQ
NurExone Biologic Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update	Apr. 02	AQ
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise	Mar. 27	AQ
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN	Mar. 22	AQ
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence	Mar. 15	AQ
NurExone Biologic Building a Research and Development Facility in Israel	Mar. 08	MT
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel	Mar. 08	AQ
NurExone Biologic Inc. Establishes Research and Development Facility in Haifa, Israel	Mar. 08	CI
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit	Mar. 01	AQ
NurExone’s Intellectual Property Portfolio Expands	Feb. 20	AQ
NurExone Biologic Inc. Expands Intellectual Property Portfolio	Feb. 20	CI
NurExone Launches Licensing Efforts For ExoTherapy Platform	Feb. 14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News NurExone Biologic Inc. Toronto S.E.

Equities

ENER

CA29278Q1063

Summary

Filters